Russell Mapes

500 total citations
11 papers, 389 citations indexed

About

Russell Mapes is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Russell Mapes has authored 11 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Russell Mapes's work include Multiple Myeloma Research and Treatments (11 papers), Peptidase Inhibition and Analysis (6 papers) and Protein Degradation and Inhibitors (5 papers). Russell Mapes is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Peptidase Inhibition and Analysis (6 papers) and Protein Degradation and Inhibitors (5 papers). Russell Mapes collaborates with scholars based in United States. Russell Mapes's co-authors include James R. Berenson, Regina A. Swift, Blake Morrison, Howard Yeh, Hank H. Yang, Jeffrey Matous, Robert Vescio, Julian Adams, Matthew B. Purner and David P. Schenkein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Russell Mapes

10 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Russell Mapes United States	8	308	275	158	21	20	11	389
Blake Morrison United States	5	268 0.9×	226 0.8×	119 0.8×	21 1.0×	19 0.9×	5	328
Zineb Benderra France	7	193 0.6×	85 0.3×	290 1.8×	22 1.0×	22 1.1×	7	374
W. S. Dalton United States	6	176 0.6×	40 0.1×	214 1.4×	15 0.7×	16 0.8×	6	328
Supinya Iamsawat United States	10	105 0.3×	105 0.4×	97 0.6×	12 0.6×	7 0.3×	19	372
Paloma Silva de Souza Brazil	12	194 0.6×	104 0.4×	114 0.7×	4 0.2×	18 0.9×	15	333
Clara Ricci Italy	7	173 0.6×	227 0.8×	40 0.3×	3 0.1×	17 0.8×	9	367
James Carmichael United States	5	273 0.9×	139 0.5×	94 0.6×	9 0.4×	4 0.2×	11	325
Emanuela Ferrari Italy	9	228 0.7×	51 0.2×	57 0.4×	4 0.2×	25 1.3×	13	298
Victoria Ling Australia	6	143 0.5×	28 0.1×	140 0.9×	13 0.6×	14 0.7×	12	270
Debra C. Ferguson United States	8	239 0.8×	22 0.1×	94 0.6×	29 1.4×	10 0.5×	14	341

Countries citing papers authored by Russell Mapes

Since Specialization

Citations

This map shows the geographic impact of Russell Mapes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russell Mapes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russell Mapes more than expected).

Fields of papers citing papers by Russell Mapes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russell Mapes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russell Mapes. The network helps show where Russell Mapes may publish in the future.

Co-authorship network of co-authors of Russell Mapes

This figure shows the co-authorship network connecting the top 25 collaborators of Russell Mapes. A scholar is included among the top collaborators of Russell Mapes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Russell Mapes. Russell Mapes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2011). A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. British Journal of Haematology. 155(5). 580–587. 25 indexed citations

Waterman, Gabriel N., et al.. (2010). A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Annals of Hematology. 90(2). 193–200. 12 indexed citations

Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2009). A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 15(3). 1069–1075. 29 indexed citations

Berenson, James R., et al.. (2009). A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. Journal of Clinical Oncology. 27(15_suppl). e19508–e19508. 7 indexed citations

Berenson, James R., Hank H. Yang, Robert Vescio, et al.. (2008). Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Annals of Hematology. 87(8). 623–631. 31 indexed citations

Berenson, James R., Jeffrey Matous, Regina A. Swift, et al.. (2007). A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 13(6). 1762–1768. 100 indexed citations

Berenson, James R., et al.. (2006). A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma. Journal of Clinical Oncology. 24(18_suppl). 7611–7611. 4 indexed citations

Berenson, James R., Hank H. Yang, Robert Vescio, et al.. (2006). Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology. 24(6). 937–944. 166 indexed citations

Berenson, James R., et al.. (2006). Phase I Study of Bortezomib and 153Sm-Lexidronam Combination for Refractory and Relapsed Multiple Myeloma.. Blood. 108(11). 3544–3544. 1 indexed citations

10.

Swift, Regina A., et al.. (2006). Phase I study of bortezomib and ¹⁵³Sm-lexidronam combination for refractory and relapsed multiple myeloma. Journal of Clinical Oncology. 24(18_suppl). 7614–7614. 4 indexed citations

11.

Berenson, James R., et al.. (2005). A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.. Blood. 106(11). 2565–2565. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact